2015
Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]
Paidas M, Frieling J, de Jongh J, Drenth H, Streisand J. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. Obstetrics And Gynecology 2015, 125: 52s. DOI: 10.1097/01.aog.0000463689.71574.8f.Peer-Reviewed Original ResearchEarly-onset preeclampsiaRecombinant human antithrombinPhase 3 trialPopulation pharmacokinetic modelingHuman antithrombinAntithrombin deficiencyPlasma antithrombinPharmacokinetic modelingHereditary antithrombin deficiencyPopulation pharmacokinetic modelAntithrombin activity levelsDifferent pharmacokinetic propertiesPrior human studiesExpectant managementPerinatal morbidityPregnant patientsLoading doseMaternal administrationPregnant womenContinuous infusionSimilar efficacyClinical studiesPleiotropic effectsAntithrombin treatmentDose selection
2013
347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD)
Paidas M, Triche E, James A, Ballard T, Lowry S. 347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD). American Journal Of Obstetrics And Gynecology 2013, 208: s154. DOI: 10.1016/j.ajog.2012.10.512.Peer-Reviewed Original Research
2006
Inherited Thrombophilias and Early Pregnancy Loss
Langhoff-Roos J, Paidas M, Ku D, Arkel Y, Loekwood C. Inherited Thrombophilias and Early Pregnancy Loss. Medical Intelligence Unit 2006, 229-243. DOI: 10.1007/0-387-34944-8_20.Peer-Reviewed Original ResearchFactor V LeidenThrombophilic conditionsPregnancy complicationsClinical manifestationsV LeidenFirst trimester pregnancy outcomeHeterozygous factor V LeidenIntrauterine growth restrictionLate fetal lossEarly pregnancy lossMaternal thromboembolismThrombogenic mutationsAbruptio placentaePregnancy outcomesProthrombotic conditionsPregnancy lossFetal lossGrowth restrictionAntithrombin deficiencyClinical practiceHeterogeneous groupComplicationsThrombophiliaDominant conditionCurrent knowledge